BEDMINSTER, N.J., March 6 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:
NPSP) announced today that it will report its 2007 financial results on
Thursday, March 13, 2008 post-market. The announcement will be followed by a
conference call and webcast at 5:00 p.m. Eastern Time.
To participate in the conference call, dial (866) 510-0708 and use
passcode 19613979. International callers may dial (617) 597-5377, using the
same passcode. In addition, a live audio of the conference call will be
available over the Internet. Interested parties can access the event through
the NPS website, http://www.npsp.com.
If you are unable to participate in the live call, a replay will be
available at (888) 286-8010, with passcode 39947050, until midnight Eastern
Time, March 28, 2008. International callers may access the replay by dialing
(617) 801-6888, using the same passcode. The webcast will also be available
through the NPS website for the same period.
About NPS Pharmaceuticals
NPS Pharmaceuticals is developing high value specialty therapeutics for
gastrointestinal and endocrine disorders. The company is currently advancing
two late-stage programs: GATTEX(TM) (teduglutide) is in Phase 3 clinical
development for intestinal failure associated with short bowel syndrome and
parathyroid hormone 1-84 [rDNA origin] injection is in Phase 2 clinical
development as a hormone therapy for hypoparathyroidism. NPS has also
completed a Phase 3 osteoporosis study for PREOS(R) (parathyroid hormone 1-84
[rDNA origin] injection). NPS complements its internal programs with
strategic partnerships, which include Amgen, GlaxoSmithKline, Kirin, and
Nycomed. Additional information is available at http://www.npsp.com.
For further information:
For further information: Gail Brophy of NPS Pharmaceuticals, Inc.,
+1-908-450-5335 Web Site: http://www.npsp.com